BioPharma Credit PLC Result of AGM
13 June 2024 - 12:09AM
RNS Regulatory News
RNS Number : 1955S
BioPharma Credit PLC
12 June 2024
BIOPHARMA CREDIT
PLC
(THE
"COMPANY")
RESULT OF 2024 ANNUAL GENERAL
MEETING
The Company is pleased to announce
that, at the Annual General Meeting held today, all resolutions put
to the meeting were passed by way of a poll.
Resolutions
|
Votes
For
|
%
|
Votes
Against
|
%
|
Total
Votes
|
% of Total Voting
Rights Voted
|
Votes
Withheld1
|
1: To receive and
accept the annual report and financial statements
|
558,898,973
|
99.99%
|
52,892
|
0.01%
|
558,951,865
|
45.85%
|
28,112
|
2: To approve the
Directors' Remuneration Report
|
558,576,994
|
99.97%
|
177,879
|
0.03%
|
558,754,873
|
45.83%
|
225,104
|
3: To receive and
approve the Directors' Remuneration Policy
|
558,551,021
|
99.96%
|
227,616
|
0.04%
|
558,778,637
|
45.84%
|
201,340
|
4: To re-elect Harry
Hyman as a Director
|
494,888,417
|
99.99%
|
66,478
|
0.01%
|
494,954,895
|
40.60%
|
64,025,082
|
5: To re-elect Colin
Bond as a Director
|
558,759,159
|
99.99%
|
76,104
|
0.01%
|
558,835,263
|
45.84%
|
144,714
|
6: To re-elect Duncan
Budge as a Director
|
494,888,417
|
88.56%
|
63,946,846
|
11.44%
|
558,835,263
|
45.84%
|
144,714
|
7: To re-elect
Stephanie Léouzon as a Director
|
558,780,785
|
99.99%
|
54,478
|
0.01%
|
558,835,263
|
45.84%
|
144,714
|
8: To re-elect Sapna
Shah as a Director
|
558,780,762
|
99.99%
|
54,478
|
0.01%
|
558,835,240
|
45.84%
|
144,737
|
9: To re-elect Rolf
Soderstrom as a Director
|
558,744,159
|
99.99%
|
76,104
|
0.01%
|
558,820,263
|
45.84%
|
159,714
|
10: To re-appoint
Ernst & Young LLP as Auditor to the Company
|
558,682,815
|
99.96%
|
204,636
|
0.04%
|
558,887,451
|
45.84%
|
92,526
|
11: To authorise the
Directors to determine the remuneration of the
Auditor
|
558,769,161
|
99.99%
|
69,478
|
0.01%
|
558,838,639
|
45.84%
|
141,338
|
12: To approve the
Company's dividend payment policy
|
558,978,176
|
100.00%
|
1,801
|
0.00%
|
558,979,977
|
45.85%
|
0
|
13: To authorise the
allotment of shares by the Company
|
556,785,857
|
99.62%
|
2,150,350
|
0.38%
|
558,936,207
|
45.85%
|
43,770
|
14: To authorise the
disapplication of pre-emption rights
|
556,858,554
|
99.63%
|
2,077,653
|
0.37%
|
558,936,207
|
45.85%
|
43,770
|
15: To authorise the
Company to make market purchases
of ordinary
shares
|
558,895,163
|
99.98%
|
84,814
|
0.02%
|
558,979,977
|
45.85%
|
0
|
16: To authorise the
Company to hold general meetings
on 14 clear days'
notice
|
558,867,851
|
99.98%
|
99,598
|
0.02%
|
558,967,449
|
45.85%
|
12,528
|
1. A 'vote
withheld' is not a vote under English law and is not counted in the
calculation of votes 'for' or 'against' a resolution.
Copies of resolutions 13 to 16 have
been submitted to the National Storage Mechanism and will shortly
be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
12 June 2024
Enquiries
BioPharma Credit plc
via Link Company Matters
Limited
Company Secretary
T. +44 (0) 333 300
1950
Buchanan
David Rydell / Mark Court
/ Jamie Hooper / Henry Wilson
+44 (0) 20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's
only listed specialist investor in debt from the life sciences
industry and joined the LSE on 27 March 2017. The Company seeks to
provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences
industry. The Company seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other
cash flows derived from the sales of approved life sciences
products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGSFIFLEELSESM
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From May 2024 to Jun 2024
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Jun 2023 to Jun 2024